EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark CYTOMX was filed as Word mark on 10/19/2017 at the European Union Intellectual Property Office.
It was registered as a trademark on 03/05/2018.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 017366717 |
| Application date | October 19, 2017 |
| Publication date | November 27, 2017 |
| Entry date | March 5, 2018 |
| Expiration date | October 19, 2027 |
Trademark owner
151 Oyster Point Blvd, Suite 400
94080 South San Francisco
US
94080 South San Francisco
US
Trademark representatives
Waterways House, Grand Canal Quay
D02 PD39 Dublin
IE
goods and services
1
Biochemicals, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic and therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use
5
Biological drugs for use in treating cancer, infections, autoimmunity, and inflammation; therapeutic and diagnostic agents and preparations for use in therapies and diagnosis for cancer, infections, autoimmunity, and inflammation; biochemicals, immunoglobulins and antigen-binding fragments for use in therapies and diagnosis for cancer, infections, autoimmunity, and inflammation; engineered cell therapies for medical purposes, namely for use in treating cancer, infections, autoimmunity, and inflammation; therapeutic and diagnostic agents, preparations and substances for medical purposes; immune modulators, immunoglobulin drug conjugates, immunotherapies and therapeutic and diagnostic agents, preparations and substances in the field of dysregulated proteolytic activity for medical purposes; immunotherapies and therapeutic and diagnostic agents, preparations and substances in the field of cancer, infections, autoimmunity, and inflammation for medical purposes; assays and reagents for use in medical, diagnostic and therapeutic purposes; biochemical test kits comprised of assays and reagents for medical, diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments
42
Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific, diagnostic and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy; proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific, diagnostic and medical purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| January 12, 2024 | Change Representative, Published | ||
| April 6, 2021 | Change Representative, Published | ||
| January 22, 2021 | Change Representative, Published | ||
| March 16, 2020 | Change Representative, Published |
ID: 11017366717